Legal Representation
Attorney
Ian W. Gillies
USPTO Deadlines
Next Deadline
117 days remaining
NOA E-Mailed - SOU Required
Due Date
April 14, 2026
Extension Available
Until October 14, 2026
Application History
15 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 15, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 14, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 19, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 19, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 13, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 16, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 12, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 12, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 12, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 13, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 13, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 13, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 13, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 12, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 30, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
drug discovery, pharmaceutical drug development, and drug validation services in the field of targeted disease-causing or disease-associated protein degradation; pharmaceutical research and development services, in particular for identifying ubiquitin ligases; providing medical research and scientific information related to ubiquitin ligase identification and targeted disease-causing or disease-associated protein degradation in the fields of pharmaceuticals, biological life sciences, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, and medical research information related to targeted disease-causing or disease-associated protein degradation in the field of pharmaceutical and clinical trials via the internet; consulting services in the fields of pharmaceutical research, biological life sciences, pharmaceutical chemistry, biochemistry, biotechnology, clinical trials, all related to targeted disease-causing or disease-associated protein degradation; research and development of new products in the field of targeted disease-causing or disease-associated protein degradation and the identification of ubiquitin ligases; pharmaceutical, scientific, medical, and clinical research and development services in the field of targeted disease-causing or disease-associated protein degradation; providing information about scientific, pharmaceutical, clinical, and medical research, namely, drug discovery, development and validation information related to a method of ligase selection to discover molecules and drugs that cause targeted disease-causing or disease-associated protein degradation; Scientific and technological services, namely, technical biology consulting services, in particular for identifying ubiquitin ligases
Additional Information
Pseudo Mark
RITE THREE
Classification
International Classes
042